{"name":"Helsinn Healthcare SA","slug":"helsinn-healthcare-sa","ticker":"","exchange":"","domain":"helsinnhealthcare.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"Netupitant and Palonosetron Phase 3 readout (Electroacupuncture, Olanzapine-contained Four-drug Antiemetic)","drug":"Netupitant and Palonosetron","drugSlug":"netupitant-and-palonosetron","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-30","label":"Netupitant and Palonosetron Phase 3 readout (Standard Quadruple Antiemetic Therapy, Electroacupuncture)","drug":"Netupitant and Palonosetron","drugSlug":"netupitant-and-palonosetron","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"I.V. palonosetron","genericName":"I.V. palonosetron","slug":"i-v-palonosetron","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)","status":"phase_3"},{"name":"Akynzeo solution","genericName":"Akynzeo solution","slug":"akynzeo-solution","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","status":"marketed"},{"name":"Oral palonosetron","genericName":"Oral palonosetron","slug":"oral-palonosetron","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)","status":"phase_3"},{"name":"Placebo to Ondansetron","genericName":"Placebo to Ondansetron","slug":"placebo-to-ondansetron","indication":"Chemotherapy-induced nausea and vomiting (CINV)","status":"phase_3"},{"name":"Placebo to Palonosetron","genericName":"Placebo to Palonosetron","slug":"placebo-to-palonosetron","indication":"Prevention of acute nausea and vomiting caused by moderately emetogenic chemotherapy","status":"phase_3"},{"name":"Pro-netupitant/Palonosetron","genericName":"Pro-netupitant/Palonosetron","slug":"pro-netupitant-palonosetron","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)","status":"phase_3"},{"name":"fosnetupitant/ palonosetron","genericName":"fosnetupitant/ palonosetron","slug":"fosnetupitant-palonosetron","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Netupitant and Palonosetron","genericName":"Netupitant and Palonosetron","slug":"netupitant-and-palonosetron","indication":"Neuroscience","status":"discontinued"}]}],"pipeline":[{"name":"I.V. palonosetron","genericName":"I.V. palonosetron","slug":"i-v-palonosetron","phase":"phase_3","mechanism":"Palonosetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)","Prevention of post-operative nausea and vomiting (PONV)"],"catalyst":""},{"name":"Akynzeo solution","genericName":"Akynzeo solution","slug":"akynzeo-solution","phase":"marketed","mechanism":"Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) that prevents chemotherapy-induced nausea and vomiting by blocking two key pathways in the chemoreceptor trigger zone and gastrointestinal tract.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","Prevention of CINV in patients receiving moderately emetogenic chemotherapy"],"catalyst":""},{"name":"Netupitant and Palonosetron","genericName":"Netupitant and Palonosetron","slug":"netupitant-and-palonosetron","phase":"discontinued","mechanism":"12.1 Mechanism of Action Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Palonosetron is a 5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. Chemotherapeutic agents produce nausea and vomiting by stimulating the release of serotonin from the enterochromaffin cells of the small intestine. Serotonin then activates 5-HT 3 receptors located on vagal afferents to initiate the vomiting reflex. The development of acute emesis is known to depend on serotonin and its 5-HT 3 receptors have been demonstrated to selectively stimulate the emetic response. Delayed emesis has been largely associated with the activation of tachykinin family neurokinin 1 (NK-1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.","indications":[],"catalyst":""},{"name":"Oral palonosetron","genericName":"Oral palonosetron","slug":"oral-palonosetron","phase":"phase_3","mechanism":"Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)","Prevention of postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"Placebo to Ondansetron","genericName":"Placebo to Ondansetron","slug":"placebo-to-ondansetron","phase":"phase_3","mechanism":"Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.","indications":["Chemotherapy-induced nausea and vomiting (CINV)","Postoperative nausea and vomiting (PONV)","Radiation-induced nausea and vomiting"],"catalyst":""},{"name":"Placebo to Palonosetron","genericName":"Placebo to Palonosetron","slug":"placebo-to-palonosetron","phase":"phase_3","mechanism":"Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting caused by chemotherapy.","indications":["Prevention of acute nausea and vomiting caused by moderately emetogenic chemotherapy","Prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy"],"catalyst":""},{"name":"Pro-netupitant/Palonosetron","genericName":"Pro-netupitant/Palonosetron","slug":"pro-netupitant-palonosetron","phase":"phase_3","mechanism":"Pro-netupitant is a substance P/neurokinin 1 (NK1) receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)"],"catalyst":""},{"name":"fosnetupitant/ palonosetron","genericName":"fosnetupitant/ palonosetron","slug":"fosnetupitant-palonosetron","phase":"marketed","mechanism":"Fosnetupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist that together prevent chemotherapy-induced nausea and vomiting (CINV) by blocking two distinct pathways in the chemoreceptor trigger zone and gastrointestinal tract.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-01","type":"patent","source":"Live Law","summary":"Delhi High Court Rejects Zydus Plea Against Helsinn's Nausea Medication Patent - Live Law","headline":"Delhi High Court Rejects Zydus Plea Against Helsinn's Nausea Medication Patent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQYy1uVDNmMnBKVE5PQ19oYXVjZGlKTk4xRjJyc2ttSjBiZjIyNDRuSzAyVl9PalJMdU5vS1gyZGIwYlgzUlp4X3BLUHJvc1JXRXFiQzZiLXo2T0tpZ3d0WG1UNWptSDU5dHZoN2J5RUV2M0RZVFA1UWFOZ1U0Q1B2dGJvVVBlNG9INk9kZUNlMzVmZw?oc=5","date":"2025-04-04","type":"deal","source":"Speciality Chemicals Magazine","summary":"HAS Healthcare Advanced Synthesis acquires Cerbios Pharma - Speciality Chemicals Magazine","headline":"HAS Healthcare Advanced Synthesis acquires Cerbios Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPbi04eXJOX3dZU0tQVVBBNEVMNUFUQTVid29IR0hYdTZXOVRTNGIwZTZFaE9Ha2dHVHc4RWhTYjAwei1QV1d4R1RuYVpuLUZKeXVHZ3k5VVNZOXpXSGo3YzVBZTBqWDRNUkpUQ2RXUHo2ZVZaRVV5bExKdm5MaGEtc3BIU3JMNjAyOGkxYjNhMFVXaXBPVnIwcDVSTTY3ejdsODg0WjlvOF9oaE5yN0pCdUVMWWJLcFF6ZFp4TElCSjcwNlVmaXdjQnlYTGY4UUhNZjRMazg0T1BCNDYxb2JWQmRBcFYtcmRFSkJPZlhEQk1WS1FHQ045MFJjUWhCblp6QTZwcjcwRVhKTDVacDFDYkx6SFQ0R055bkRDa3lBU2c0MWpHX2VkdGpiNzNway16Ymkwb1Qwc0F2WEU?oc=5","date":"2025-01-28","type":"pipeline","source":"globenewswire.com","summary":"Knight Therapeutics and Helsinn Healthcare SA Expand - globenewswire.com","headline":"Knight Therapeutics and Helsinn Healthcare SA Expand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gJBVV95cUxOczVpV3BmaklpUjY3UEN1djV2bWVzRWVQOXBsWmNkRTh5a0xFZEV2eUxvcXFxbW5iaVlqT2dPUXpYV0V1LW9Pem9EQjNKeVN2cWpqZ0loQ1p6Tkp1R1ZmemswWXRhNExpYllDZXAwaHdNazlVNV9aSlJTOEVlNW9qRFNhbHdoQ2ZpYVRWb3E4VmZZNGhfRExRZWFTVzlya3dRbGZHUUZ2c0JvNldGVDBkUnUzaEp4ZERzbnI3QVc0cUYwNFI5aHJWNGRUTzdFYWpDV2VvLXBZN3ZwOG4wbHlWeWYwVHNYYUZuekZrTFhXMk1ZdVFYbnVQX3MxbkpidG1paTNmeFE1dEdNZlBhWkJBczBlbjZVXzBabTU0WmRWTUNIOXI5UzJ3bHZCQjZNcm45UWNGUVVGUmpOeU5nT0g2bjVDb1pCZ2RhZW10UDl1dGQyUHBIZV9yRjdrSWJzQQ?oc=5","date":"2024-05-27","type":"deal","source":"globenewswire.com","summary":"Helsinn and Angelini Pharma sign a partnership agreement - globenewswire.com","headline":"Helsinn and Angelini Pharma sign a partnership agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxQT0dZRWVjVmdtcW1SZ1YyNy03dV9UT1dCLTEzUFRvOXZCWGdQY3BadEV1dnZqREVQLWJiS0xDRXpzLTk1QUFoeGhrRkhpVXRTbmpoeWdzODdTQjBtSnNEdUVfbXpWVkZYa1Z2WGFzYVdSS05kYkJVWi1JY210dmJZOFVwYlQzYWN4Yk1yRWtEbXgzTjd5UFBvQ2V5eFYzSnloYVZzb3ZHaHhXNTJmbzh3enBwTzBEOGVYQmdDWnRMS1Y2Smh0S19vTVpwbFFlOHI1TUFyRzBQRjRoNjVBOGMwY2ZCQ1JESXJiaThmRnFkaHB6VFBnamNTRnlNaEJ1b2pQaW9RZWNMSnRObzAyQUdKNm80d2hGdDZNNWJ1WEZad1F3SUctX2pUWnpqS1BJdlhfNnVGYXprdU1YZnZxQkF6VWlR?oc=5","date":"2022-09-01","type":"deal","source":"globenewswire.com","summary":"Helsinn Healthcare SA signs exclusive license agreement - globenewswire.com","headline":"Helsinn Healthcare SA signs exclusive license agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOajhhUHBXc2JQRE9oTVJVS1Z5SFVCMWYxVlNiSW02VnNsdmp1MTVXSld3ZHYwTDU4UVhJTWJYTVpkSVBQLUUtWjRSTWVrZnliT1IwY1kzVGRwMGxiLWVCQWQ2OENIcDI3SXFSQ21KcnowVWZwYWdZQ3BNTHY3SW5SYURyand2c2I4dEFSNll0RXJkc1JQdGZ6OXhZSi1NMy1nR1V1Z1VkV0tlbUU?oc=5","date":"2022-03-31","type":"pipeline","source":"DCAT Value Chain Insights","summary":"News from DCAT Week 2022: HAS Healthcare Advanced Synthesis Outlines Multi-Year Expansion Plan - DCAT Value Chain Insights","headline":"News from DCAT Week 2022: HAS Healthcare Advanced Synthesis Outlines Multi-Year Expansion Plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOXzdWN2lhMGNoVEtoZHBmVjFRZnZjMldxZWs1cEIyeXlxVFhxY0lEUmR5RXFydmFJQlYwaC03OU9Ia25DdHMtUXRkaG1yazByOUhVb2tES0N0MTBsWmtqVUNwRkN1QTlCMW5kMTRkdFY2Ym9VeVR1RC1PaDdBZUNjZE15THlFUQ?oc=5","date":"2019-12-06","type":"pipeline","source":"Nixon Peabody","summary":"SCOTUS Helsinn decision - Intellectual Property Alert - Nixon Peabody","headline":"SCOTUS Helsinn decision - Intellectual Property Alert","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNVDBQVjR4bG5JbElrU09QTWxDdUxnUkFrTUttZzN1WXhOamdwVmwxZGVJUEkwSUowUnVaMmo4Y0FXQXM2TnBJZ2l1WlZsbktWZmpHQ0J3amFIbzN0QXc1S2FlNFZxbmFKc0FucE1wUjNDaXlqV2syX3AyQkNqYXJmTw?oc=5","date":"2019-01-22","type":"pipeline","source":"IPWatchdog.com","summary":"Supreme Court decides Helsinn v. Teva, Secret Sale Qualifies as Prior Art Under the AIA - IPWatchdog.com","headline":"Supreme Court decides Helsinn v. Teva, Secret Sale Qualifies as Prior Art Under the AIA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQOEl0V1EtaFExSDJYSGhZV2dUZFV1amJ6OUcxQnJJZE95eTIxRElzX3EzQkhaUVVkMHBOUXZKYmNGLUxUenNWdWxaM1B0N2ZXd184Y01HSUZEWWpZUlZQLXRqZUZyN0VVdXBfYmk0Y2ZxSmlVcTY4WDYyQ182MjZNS1dENjdNNWRGTW9ST0lmM3ViaE1mMHM0UTRB?oc=5","date":"2019-01-22","type":"pipeline","source":"Jones Day","summary":"Secret Sales Are Still Prior Art: U.S. Supreme Court Affirms Helsinn Healthcare - Jones Day","headline":"Secret Sales Are Still Prior Art: U.S. Supreme Court Affirms Helsinn Healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBCcXhNSTJ2V2FlZ0hqYzMxWWh2T05YcjJOejlWbW5sdmhldHZTYWx1YUEzVXFya1piUnpFb3VJNEF3c3ROUGxVQVhQY0Nmb2pyaVIxYWtzcDlxUWprc0dtSXFFR1dBUU5CSXA0cUVJbm1YMnFhMkQyWi16b9IBe0FVX3lxTFBCcXhNSTJ2V2FlZ0hqYzMxWWh2T05YcjJOejlWbW5sdmhldHZTYWx1YUEzVXFya1piUnpFb3VJNEF3c3ROUGxVQVhQY0Nmb2pyaVIxYWtzcDlxUWprc0dtSXFFR1dBUU5CSXA0cUVJbm1YMnFhMkQyWi16bw?oc=5","date":"2017-05-30","type":"pipeline","source":"The National Law Review","summary":"On-Sale Bar Under the America Invents Act - The National Law Review","headline":"On-Sale Bar Under the America Invents Act","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQY2xTQnREN1ozNmd2d3lyM0VoWTVGQTlZUlprYjFWcDM4S25xM21tRWptWmNSeVVUTzUwSnZYaE5CWkZzY1psdEg3Vi1UYlBSUld0bFV2ZGhqVmZUNlFjUjNQVWY3MHhlQVExMXhFVUxWY1lwall5NTB0UkN6am5rQnNNMDl0QVFyemRxTnVDdDNOWTBwT1FoaWNXSU9nMnNvR252WHVKZkJZSG9kdjBOb0ZGVjgwamM?oc=5","date":"2017-02-17","type":"earnings","source":"NDTV Profit","summary":"DR Reddy's Says No Claims For Monetary Damages In US Patent Case - NDTV Profit","headline":"DR Reddy's Says No Claims For Monetary Damages In US Patent Case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOMEFiUVpxaGhFcVRUY1Zhay10MXFyYzA3RExiaGhUdVktcjE2ck93cjIzX2stUkNXeWdZMXBlM0NocFFCdERoUmpkWVRYR0lTZW1TTm9qSGI3SExrQW1mcXRlUU9hbDUtVk1uVGFqQ29WTzNrV1ZTWnpYOGtNX2NGdm5kVld3RjB3bHpSN3hpVGxBWS13M0lLNTgzWl9hN3BtaW9GWjNEMFFmX0F6b0l5dXFlZ2dRa2w4dFA5MndoTURkUV9N?oc=5","date":"2007-07-09","type":"regulatory","source":"RTTNews","summary":"MGI Pharma, Helsinn Announce Aloxi SNDA For PONV Accepted For Review By FDA - Quick Facts - RTTNews","headline":"MGI Pharma, Helsinn Announce Aloxi SNDA For PONV Accepted For Review By FDA - Quick Facts","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":5,"marketed":2,"discontinued":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}